

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

## EDITORIAL

### Vancomycin-Intermediate *Staphylococcus epidermidis*: Curio or Omen?

LARRY J. STRAUSBAUGH, MD

163

## ORIGINAL ARTICLES

### The Emergence of Decreased Susceptibility to Vancomycin in *Staphylococcus epidermidis*

DENISE O. GARRETT, MD; ELISE JOCHIMSEN, MD; KATE MURFIT, BS; BERTHA HILL, BS; SIGRID McALLISTER, BS; PAT NELSON, RN; RICHARD V. SPERA, MD; RICHARD K. SALL, MD; FRED C. TENOVER, PhD; JUDY JOHNSTON, MS; BARBARA ZIMMER, PhD; WILLIAM R. JARVIS, MD

167

### The Prevalence of Colonization With Vancomycin-Resistant *Enterococcus* at a Veterans' Affairs Institution

JEROME I. TOKARS, MD, MPH; SACHIKO SATAKE, PhD; DAVID RIMLAND, MD; LORETTA CARSON, MS; ELAINE R. MILLER, RN, MPH; EDNA KILLUM, RN; RONDA L. SINKOWITZ-COCHRAN, BS, MPH; MATTHEW J. ARDUINO, DRPH; FRED C. TENOVER, PhD; BARBARA MARSTON, MD; WILLIAM R. JARVIS, MD

171

### Management of a Sabiá Virus-Infected Patient in a US Hospital

LORI R. ARMSTRONG, PhD; LOUISE-MARIE DEMBRY, MD; PETRIE M. RAINEY, MD, PhD; MARK B. RUSSI, MD; ALI S. KHAN, MD; STEVEN H. FISCHER, MD, PhD; STEPHEN C. EDBERG, PhD; THOMAS G. KSIAZEK, DVM, PhD; PIERRE E. ROLLIN, MD; C.J. PETERS, MD

176

### Surgical-Site Complications Associated With a Morphine Nerve Paste Used for Postoperative Pain Control After Laminectomy

MICHAEL H. KRAMER, MD, MPH; ALICIA J. MANGRAM, MD; MICHELE L. PEARSON, MD; WILLIAM R. JARVIS, MD

183

### Epidemiology of Device-Associated Infections Related to a Long-Term Implantable Vascular Access Device

MARK J. SOTIR, MPH; CURTIS LEWIS, MD; EDWARD W. BISHER, MD; SUSAN M. RAY, MD; J. MICHAEL SOUCIE, PhD; HENRY M. BLUMBERG, MD

187

### Long-Lasting Contamination of a Vitrectomy Apparatus With *Serratia marcescens*

INES KAPPSTEIN, MD; CHRISTIAN M. SCHNEIDER, MD; HAJO GRUNDMANN, MD; REGINA SCHOLZ, RN, ICP; PETER JANKNECHT, MD

192

### Evaluation of the SENIC Risk Index in a Spanish University Hospital

VICTORIA VALLS, MD; MANUEL DIEZ, MD; JAVIER ENA, MD; ALBERTO GUTIÉRREZ, MD; PEÑA GÓMEZ-HERRUZ, MD; ANTONIO MARTÍN, MD; ROSARIO GÓNZALEZ-PALACIOS, PHARM D; JAVIER GRANELL, MD

196

## CONCISE COMMUNICATIONS

### Evaluation of a Handwashing Intervention to Reduce Respiratory Illness Rates in Senior Day-Care Centers

ANN R. FALSEY, MD; MARY M. CRIDDLE, RN; JOHN E. KOLASSA, PhD; ROBERT M. McCANN, MD; CHRISTINE A. BROWER, BS; WILLIAM J. HALL, MD

200

### Regional Dissemination and Control of Epidemic Methicillin-Resistant *Staphylococcus aureus*

LINDSAY E. NICOLLE, MD; BRENDA DYCK, BSCN; GENEVIEVE THOMPSON, RN; SUSAN ROMAN, MD; AMIN KABANI, MD; PIERRE PLOURDE, MD; MARGARET FAST, MD; JOHN EMBIL, MD; THE MANITOBA CHAPTER OF CHICA-CANADA

202

Continued inside.

# Are You Doing All You Can to Stop Methicillin-Resistant *Staphylococcus aureus* Outbreaks Where They Originate...

The Nares

- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.<sup>1</sup>
- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.<sup>2</sup>
- Excellent safety profile<sup>1</sup>

Single-use tube  
(actual size)



Please see brief summary of prescribing information on adjacent page.

**References:** 1. Bactroban® Nasal prescribing information, 1995. 2. Reagan DR, Dula RT, Palmer BH, et al. Control of MRSA in a VAMC with limited resources. Prog Abstr 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., Sept. 29-Oct. 2, 1991, p 104.

**SB** SmithKline Beecham  
Pharmaceuticals

**Bactroban®**  
**Nasal** mupirocin  
calcium

2% ointment for intranasal use

**BACTROBAN® NASAL** (mupirocin calcium ointment), 2%  
Brief summary. For complete prescribing information, see package insert.

**INDICATIONS AND USAGE**

*Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

**NOTE:**

- (1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
- (2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
- (3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

**CONTRAINDICATIONS**

*Bactroban* Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

**WARNINGS**

**AVOID CONTACT WITH THE EYES.** Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

**PRECAUTIONS**

**General:** As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See DOSAGE AND ADMINISTRATION in complete prescribing information.)

**Information for Patients:** Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

**Drug Interactions:** The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to 40 times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m<sup>2</sup> basis and revealed no evidence of impaired fertility from mupirocin sodium.

**Pregnancy: Teratogenic Effects. Pregnancy Category B.** Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m<sup>2</sup> basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

**Pediatric Use:** Safety in children under the age of 12 years has not been established. (See CLINICAL PHARMACOLOGY in complete prescribing information.)

**ADVERSE REACTIONS**

**Clinical Trials:** In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events thought to be at least possibly drug-related that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

**OVERDOSAGE**

Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories, Inc.**, San Antonio, TX 78215

Distributed by **SmithKline Beecham Pharmaceuticals**, Philadelphia, PA 19101

BN:L1

## Good medicine for your career

At St. Rita's Medical Center, a 400+ bed regional referral center located in West Central Ohio, human dignity, compassionate care and advanced medical technologies combine to provide the highest quality care. Discover professional rewards and personal satisfaction in a team-oriented environment.

### Infection Control Coordinator


#### Full Time

We have an immediate full time opportunity for an Infection Control Coordinator to manage the hospital-wide Infection Control program. Responsibilities will include originating and reviewing policies and procedures; functioning as a resource for physicians, staff, and patients; assuring compliance with regulatory guidelines; and providing orientation and continuing education for staff members.

Successful candidates must have a minimum of a B.S. degree with Medical Technology registration or an R.N. license with demonstrated problem solving, communication and data analysis skills. Knowledge of Epidemiologic Principles, sterilization and disinfection procedures also required. Must have familiarity with patient care equipment and procedures, as well as knowledge of, and experience with, state, federal and JCAHO regulations. CIC certification in Infection Control, or willing to obtain, will be required.

We offer salary commensurate with experience and flexible benefits. Qualified candidates may apply in person, or mail/fax/email resume to: **Employment Manager, St. Rita's Medical Center, 730 W. Market St., Lima, OH 45801, PH: (419) 226-9548 or 1-800-232-7762 ext. 9548, FAX: (419) 226-9870, Email: javantilburgh@health-partners.org**

St. Rita's is an equal opportunity employer.



## MEDICAL MATRIX

Ranked, Peer-Reviewed,  
Annotated, Updated,  
Clinical Medicine Resources

- MEDLINE
- NEWS
- STAT SEARCH NEW!
- JOURNALS
- RX ASSIST
- PATIENT EDUCATION
- CME
- TEXTBOOKS
- MARKETPLACE

**THE LARGEST PEER-REVIEWED,  
ANNOTATED AND RATED INTERNET  
MEDICAL DIRECTORY**

**VISIT MEDICAL MATRIX FOR  
FREE ACCESS TO THE BEST  
MEDICAL SITES ON THE WEB**

<http://www.medmatrix.org>  
(Registration Required)

Reviewed and updated continuously by an Editorial Board comprised of Physicians and Medical Informatics Specialists

For advertising opportunities contact M. Long



*The Society for Healthcare Epidemiology of America*

## 1999 SHEA/CDC

# Training Course in Hospital Epidemiology

### Program

The program will be held May 1-4, 1999 at the Wyndham Franklin Plaza Hotel, Philadelphia, Pennsylvania. Timothy W. Lane, M.D., Gina Pugliese, R.N., and Julie Gerberding, M.D. will chair the program.

### Purpose

This program, developed by the Society for Healthcare Epidemiology of America (SHEA), and the Centers for Disease Control and Prevention (CDC), is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

### Who Should Attend

You should attend if you are a hospital epidemiologist or an infection control practitioner or if you are looking for a course that will provide you the most current information concerning infection control practices and epidemiological methods in health care. This fundamental program will provide you with the opportunities to find solutions to real situations that will occur in the hospital setting. Intensive problem solving sessions are supplemented with lectures and seminars presented by leading authorities.

### Scholarships

Scholarships in the amount of \$1,000 will be awarded to infectious disease fellows for the program to defray the special course fee for fellows of \$350 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability for the course also is required. The deadline for receipt of scholarship applications for the course is March 26, 1998.

The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. Winners will be notified in September.

### Nominations

Please send scholarship applications to:

Timothy W. Lane, M.D.

c/o The Society for Healthcare Epidemiology of America

19 Mantua Road

Mt. Royal, NJ 08061

### Fees

Individual Registrants \$495

Fellows in Infectious Disease \$350

### Credits

The Society for Healthcare Epidemiology of America (SHEA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

SHEA designates this continuing education activity for up to 23 hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

The SHEA/CDC Training Course is AACN (American Association of Critical Care Nurses) approved for 28.5 hours.

### General Course Information

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from SHEA (609) 423-7222 x350. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship Awards provided in part by an educational grant from Pfizer Pharmaceuticals.



Labs • NHO • Pratt • Roerig • Specialty

U.S. Pharmaceuticals Group

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

## CONTENTS

Continued from cover

### Nosocomial Infections With Ceftazidime-Resistant

#### *Pseudomonas aeruginosa*: Risk Factors and Outcome

SAI-CHEONG LEE, MD; CHANG-PHONG FUNG, MD; PETER YUK-FONG LIU, MD, MSc; TZU-CHIEN WANG, PhD;  
LAI-CHU SEE, PhD; NING LEE, MD; SHU-CHU CHEN, RN; WEN-BIN SHIEH, MD

205

### THE INTERNATIONAL PERSPECTIVE

#### The Effect of Frequency of Chart Review on the Sensitivity of Nosocomial Infection Surveillance in General Surgery

MIGUEL DELGADO-RODRÍGUEZ, MD, PhD; ANTONIO GÓMEZ-ORTEGA, MD; ANTONIO SIERRA, MD, PhD;  
TRINIDAD DIERSSEN, MD; JAVIER LLORCA, MD, PhD; MARÍA SILLERO-ARENAS, MD, PhD

208

### LETTERS TO THE EDITOR

#### Hepatitis B and Hemodialysis: The Impact of Universal Precautions in Preventing the Transmission of Bloodborne Viruses (with reply)

ROB LYERLA, PhD; SCOTT KELLERMAN, MD, MPH; MIRIAM J. ALTER, PhD; ALOYS C.M. KROES, MD, PhD;  
ERIC F.H. VAN BOMMEL, MD, PhD; JAN A.J.W. KLUYTMANS, MD, PhD; WILLEM WEIMAR, MD, PhD

156

#### Risk of Tuberculosis Transmission in an Adult Day-Care Center

JUDITH E. WOLF, MD; JAMES L. DEAN, MD

157

#### Level of Suspicion of Pulmonary Tuberculosis Over a 4-Year Period in a Teaching Hospital

ANNIE-CLAUDE LABBÉ, MD; KARL WEISS, MD, FRCPC; MICHEL LAVERDIÈRE, MD, FRCPC; LOUISE POIRER, MD, FRCPC

158

#### Tuberculosis Contact Tracing Among Healthcare Workers: Source-Case Selection, Method of Tracing, and Outcome of Follow-Up

JOSEPH BARAN, JR, MD; HITPREET SANGHERA, MD; RIAD KHATIB, MD

160

### MEDICAL NEWS

GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PhD

213

### SHEA NEWS

ANDREAS VOSS, MD, PhD

216

To view abstracts of these articles,  
visit us on the Internet at <http://www.slackinc.com/general/iche>

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

**PUBLISHER:** Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 848-1000.

**SHEA:** 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 609-423-0087; fax, 609-423-3420; e-mail address, sheahq@talley.com.

**COPYRIGHT 1999** The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

**SUBSCRIPTIONS:** Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$105.00; Two years-\$143.00; Three years-\$176.00; Institutional: One year-\$128.00; Two years-\$178.00; Three years-\$228.00. Fellows: \$52.50 per year with proof of training status. Canada: \$20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, \$145.00 each year; Overseas air mail, \$190.00. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

**INSTRUCTIONS TO AUTHORS:** Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (<http://www.slackinc.com/general/iche/ichehome.htm>). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

**REPRINTS:** All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$1.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

**CHANGE OF ADDRESS:** Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

**INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY** is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNDex Top 100.

# NOW AVAILABLE ON CD-ROM: INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

## 1987 - 1997

Simplifying your reference library is easy, with 10 years of INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY now available on CD-ROM. As the official journal of the Society of Healthcare Epidemiology of America (SHEA), this ready reference will allow the user to quickly and easily access articles and studies from 1987-1997 that can help put current issues of epidemiology and infection control in perspective.

### Easy and Convenient CD-ROM Technology

The INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM will take full advantage of the latest CD-ROM technology, including:

- fully searchable text
- annual indexes organized by category, page number, subject and author
- convenient annual updates
- PC and Mac compatibility

The INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM packs an enormous amount of information in a small space at a comparably small price! Adding 10 years of this informative journal to your library is a bargain, at special prices starting as low as \$147.

### Money-Back Guarantee

The Society of Healthcare Epidemiology of America is always looking for innovative ways to keep you informed of important developments in infection control and hospital epidemiology. We are sure you will refer to the information in the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM often. If you aren't satisfied, we offer a 30-day money-back guarantee.\*

To order, call us at **800-257-8290** or **609-848-1000** (in NJ); or write to  
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY  
6900 Grove Rd., Thorofare, NJ 08086

Appx. pub. date: 10/98

**Yes!** Please send me the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM. Enclosed is a check or money order for the amount/quantity checked below.

|   |              |            |
|---|--------------|------------|
| <input type="checkbox"/> SHEA Member:           | \$147.00 ea. | Qty: _____ |
| <input type="checkbox"/> Individual Non-Member: | \$197.00 ea. | Qty: _____ |
| <input type="checkbox"/> Institution:           | \$247.00 ea. | Qty: _____ |

Or bill my  Visa  Mastercard  Amex

Acct. No. \_\_\_\_\_ Exp. date: \_\_\_\_/\_\_\_\_/\_\_\_\_

Signature: \_\_\_\_\_

Send CD-ROM to:

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Phone \_\_\_\_\_ FAX \_\_\_\_\_

#### Send order and make check payable to:

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY • 6900 Grove Rd. • Thorofare, NJ 08086

Or FAX your order to: (609) 853-5991

For fastest service, call today, 1-800-257-8290 or 609-848-1000 (in NJ)

\*If not completely satisfied with the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM, just return it within 30 days and your money will be refunded.



**EDITORIAL OFFICES**

Vanderbilt University School of Medicine  
A-1131 Medical Center North  
Nashville, TN 37232-2637  
(615) 343-1095; (615) 343-1882 (FAX)  
Email: iche@mcm.vanderbilt.edu

**EDITOR**

Michael D. Decker, MD, MPH

**MANAGING EDITOR**

Susan Cantrell

**STATISTICAL EDITOR**

Beverly G. Mellen, PhD

**SENIOR ASSOCIATE EDITORS**

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

**ASSOCIATE EDITORS**

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

**SECTION EDITORS****Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

**Disinfection and Sterilization**

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

**Emerging Infectious Diseases**

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

**From the Laboratory**

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

**Information Management**

John A. Sellick, DO

Buffalo, New York

**The International Perspective**

Mary D. Nettleman, MD, MS

Richmond, Virginia

**Issues in Surgery**

James T. Lee, MD, PhD

St. Paul, Minnesota

**Medical News**

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

**Practical Healthcare Epidemiology**

Loreen A. Herwaldt, MD

Iowa City, Iowa

**SHEA News**

Andreas Voss, MD, PhD

Nijmegen, The Netherlands

**Statistics for Hospital Epidemiology**

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

**Topics in Long-Term Care**

Phillip W. Smith, MD

Omaha, Nebraska

**Topics in Occupational Medicine**

David Weber, MD, MPH

Chapel Hill, North Carolina

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

## EDITORIAL ADVISORY BOARD

- Jacques F. Acar, MD  
Paris, France
- J. Wesley Alexander, MD  
Cincinnati, Ohio
- Paul Arnow, MD  
Chicago, Illinois
- Graham A.J. Ayliffe, MD  
Birmingham, United Kingdom
- Neil L. Barg, MD  
Yakima, Washington
- Elizabeth Ann Bolyard, RN, MPH, CIC  
Atlanta, Georgia
- John M. Boyce, MD  
Providence, Rhode Island
- Professor Dr. Ilja Braveny  
Munich, Federal Republic of Germany
- Charles Bryan, MD  
Columbia, South Carolina
- Christian Brun-Buisson, MD  
Creteil, France
- Donald E. Craven, MD  
Boston, Massachusetts
- Sue Crow, MSN, RN, CIC  
Shreveport, Louisiana
- Franz Daschner, MD  
Freiburg, Federal Republic of Germany
- Leigh G. Donowitz, MD  
Charlottesville, Virginia
- Charles E. Edmiston, Jr., PhD  
Milwaukee, Wisconsin
- Theodore C. Eickhoff, MD  
Denver, Colorado
- Bruce Farber, MD  
Manhasset, New York
- Victoria J. Fraser, MD  
St. Louis, Missouri
- Peter C. Fuchs, MD, PhD  
Black Butte, Oregon
- Richard A. Garibaldi, MD  
Farmington, Connecticut
- Velvi Greene, PhD, MPH  
Beer Sheva, Israel
- Robert Gaynes, MD  
Atlanta, Georgia
- David W. Gregory, MD  
Nashville, Tennessee
- David K. Henderson, MD  
Bethesda, Maryland
- Peter N.R. Heseltine, MD  
Los Angeles, California
- Karen Hoffmann, RN, CIC, MS  
Chapel Hill, North Carolina
- Marguerite McMillan Jackson, RN, PhD  
San Diego, California
- Janine Jagger, MPH, PhD  
Charlottesville, Virginia
- William R. Jarvis, MD  
Atlanta, Georgia
- Douglas S. Kernodle, MD  
Nashville, Tennessee
- Robert H. Latham, MD  
Nashville, Tennessee
- Lewis B. Lefkowitz, MD  
Nashville, Tennessee
- Hsieh-Shong Leu, MD, MSc  
Taipei, Taiwan
- Jack Levy, MD  
Brussels, Belgium
- Victor Lorian, MD  
Bronx, New York
- Dennis G. Maki, MD  
Madison, Wisconsin
- Professor Dr. Walter Marget  
Munich, Federal Republic of Germany
- William J. Martone, MD  
Bethesda, Maryland
- Allison McGeer, MD  
Toronto, Ontario, Canada
- John E. McGowan, Jr., MD  
Atlanta, Georgia
- Jonathan L. Meakins, MD, DSc  
Montreal, Quebec, Canada
- Raf Mertens, MD  
Brussels, Belgium
- Robert R. Muder, MD  
Pittsburgh, Pennsylvania
- Joseph M. Mylotte, MD, CIC  
Buffalo, New York
- Lindsay Nicolle, MD  
Winnipeg, Manitoba, Canada
- Juhani Ojajarvi, MD  
Helsinki, Finland
- Michael T. Osterholm, PhD, MPH  
Minneapolis, Minnesota
- Jan Evans Patterson, MD  
San Antonio, Texas
- Sindy M. Paul, MD  
Trenton, New Jersey
- Michael A. Pfaller, MD  
Iowa City, Iowa
- Samuel Ponce de Leon, MD, MSc  
Mexico City, Mexico
- Isaam Raad, MD  
Houston, Texas
- Manfred L. Rotter, MD, DipBact  
Vienna, Austria
- Theodore Sacks, MD  
Jerusalem, Israel
- William E. Scheckler, MD  
Madison, Wisconsin
- Kent Sepkowitz, MD  
New York City, New York
- Denis Spelman, MD  
Pahran Victoria, Australia
- Michael L. Tapper, MD  
New York, New York
- Clyde Thornsberry, PhD  
Brentwood, Tennessee
- Professor Leonid P. Titov  
Minsk, Republic of Belarus
- Timothy R. Townsend, MD  
Millwood, Virginia
- Antoni Trilla, MD, PhD  
Barcelona, Spain
- Professor Wang Shu-Qun  
Beijing, People's Republic of China
- J. John Weems, Jr., MD  
Greenville, South Carolina
- Robert A. Weinstein, MD  
Chicago, Illinois
- Professor Dr. W. Weuffen  
Greifswald, Federal Republic of Germany
- Sergio B. Wey, MD  
São Paulo, Brazil
- Rebecca Wurtz, MD  
Evanston, Illinois

**SLACK Incorporated**

6900 Grove Road  
Thorofare, New Jersey 08086  
(609) 848-1000

**Vice President/Group Publisher**

Richard N. Roash

**Publisher**

John C. Carter

**Editorial Director**

Jennifer Kilpatrick

**Production Editor**

Shirley P. Strunk, ELS

**Assistant Editor**

Eric C. Anderson

**Circulation Manager**

Lester J. Robeson, CCCP

**Production Director**

Christine Malin

**Production Coordinator**

Joanne Patterson

**Publishing Director/ Advertising**

Wayne McCourt

**Pharmaceutical Group Sales Director**

Michael J. Press

**Advertising Sales Representative**

Jennine Kane

**Classified/Recruitment Sales Manager**


Kathy Huntley

**Classified/Recruitment Sales Representative**

Kelly Wark

# ALL THE ANSWERS UNDER ONE COVER

Just Released!



## A Practical Handbook for Hospital Epidemiologists

Edited by Loreen A. Herwaldt, MD  
and co-edited by Michael D. Decker, MD, MPH

Soft Cover, 448 pp, ISBN 1-55642-302-0, Order# 13020, \$60.00

**A Practical Handbook for Hospital Epidemiologists** is the most complete source for practical advice on hospital epidemiology. It is intended to be a pragmatic guide that will assist both beginning and experienced epidemiologists in establishing and operating a successful hospital epidemiology program.

This handbook will supplement the various scientific references already available for hospital epidemiologists. It will provide practical information and advice regarding many aspects of operating a hospital epidemiology program and will help hospital epidemiologists improve their practices.

The Society for Healthcare Epidemiology of America (SHEA) has recruited the most recognized leaders in

the field to share their expertise. They will share successful strategies for handling specific situations. The authors cover many topics that every newcomer should know but are usually learned through experience. These topics include:

- **Overarching goals and ethical principles you should adopt to guide your practice**
- **What you can do to educate yourself**
- **How to negotiate with the administration and communicate with colleagues**
- **How to develop policies and procedures**
- **How to develop a surveillance system**

## Contents

### Getting Started

Chapter 1: An Introduction to Practical Hospital Epidemiology

Chapter 2: The Hospital Epidemiologist: Practical Ideas

Chapter 3: Educational Needs and Opportunities for the Hospital Epidemiologist

Chapter 4: Negotiating with the Administration—or How to Get Paid for Doing Hospital Epidemiology

Chapter 5: The Infection Control Committee

Chapter 6: Developing Policies and Guidelines

Chapter 7: Intramural and Extramural Communication

Chapter 8: Ethical Aspects of Infection Control

### Surveillance and Analysis

Chapter 9: Basics of Surveillance—An Overview

Chapter 10: Hospital-Acquired Pneumonia: Perspectives for the Healthcare Epidemiologist

Chapter 11: Basics of Surgical Site Infection Surveillance

Chapter 12: Surveillance for Infections Associated with Vascular Catheters

Chapter 13: Designing Surveillance for Noninfectious Outcomes of Medical Care

Chapter 14: Outbreak Investigations

Chapter 15: Exposure Workups

Chapter 16: Isolation

Chapter 17: Basics of Stratifying for Severity of Illness

Chapter 18: Quantitative Epidemiology

### Support Functions

Chapter 19: Microcomputers in Hospital Epidemiology

Chapter 20: The Computer-Based Patient Record: The Role of the Hospital Epidemiologist

Chapter 21: Basic Microbiologic Support for Hospital Epidemiology

Chapter 22: Epidemiologic Typing Systems

### Special Topics

Chapter 23: Epidemiologic Approaches to Quality Assessment

Chapter 24: Disinfection and Sterilization of Patient Care Items

Chapter 25: Controlling Use of Antimicrobial Agents

Chapter 26: Employee Health and Infection Control

Chapter 27: Tuberculosis Control in Healthcare

Chapter 28: Infection Control Issues in Construction and Renovation

Chapter 29: Hospital Epidemiology in Smaller Hospitals

Chapter 30: Infection Control in Public Hospitals

Chapter 31: Infection Control in Long-Term Care Facilities

Chapter 32: Infection Control in the Outpatient Setting

Chapter 33: OSHA Inspections

Chapter 34: Preparing for and Surviving a JCAHO Inspection

Chapter 35: Product Evaluation

## Order Coupon

Yes, Send me  copies of *A Practical Handbook for Hospital Epidemiologists* (Order# 13020) at the Special Introductory Price of **\$60.00** each. (Shipping may apply.) Foreign orders add \$25.00 USD for direct air-freight shipping to your location.

Subtotal \$ \_\_\_\_\_  
Handling charge \$ 4.50  
NJ residents add 6% sales tax \$ \_\_\_\_\_  
Total \$ \_\_\_\_\_

### Please print

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_

State/Country \_\_\_\_\_

Zip \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Check enclosed (payable to SLACK Inc., in US dollars drawn on a US bank)

Charge My  Visa  Mastercard  American Express

Account No. \_\_\_\_\_ Exp. \_\_\_\_\_

Signature \_\_\_\_\_

SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086-9447, USA

To order call (in the US) 800-257-8290 or 609-848-1000  
Fax orders to 609-853-5991

Order on-line: [orders@slackinc.com](mailto:orders@slackinc.com)  
<http://www.slackinc.com>

All Prices Are Subject To Change

CODE 4A345



**SHEA**

**CDC Guidelines  
for Surveillance  
Prevention & Control  
of Nosocomial  
Infections**

**All In One  
Single Volume  
for only \$99.00\***

Plus Shipping  
& Handling

Urinary Tract Infections • Surgical Wound Infections  
Handwashing and Environmental Control  
Hospital Personnel • HIV and HBV Exposure-  
Prone Procedures • Pneumonia Tuberculosis  
Vancomycin Resistance • IV Device-Related  
Infections • Isolation Precautions  
HIV Post-Exposure Chemoprophylaxis  
HCV Post-Exposure Prophylaxis  
**and** Index of SHEA Position Papers

**Foreword by Julia S. Garner, RN, MN**

**To Order Call 1-800-552-0076**

International Orders 414-634-0806  
E-mail ETNAComm@aol.com

\*SHEA Journal Subscribers mention this ad for 10% discount.  
Orders outside the U.S.A., Canada, & Mexico are \$175.00 each.

SJ198

# Finding the source of an infection in hours, not days.

A university teaching hospital noted increased infections caused by an antibiotic-resistant strain of *Pseudomonas aeruginosa*. Physicians noted resistance to imipenem, but were perplexed because, of the patients who cultured positive for the strain, only 15% had received imipenem.

The RiboPrinter® Microbial Characterization System took only eight hours to genetically fingerprint isolates and revealed that 85% of the infected patients shared the identical strain of *P. aeruginosa*. When hospital epidemiologists found that 85% of these patients had been intubated in the Shock Trauma Center (STC), they knew the increased incidence was due to nosocomial transmission.

Environmental culturing turned up *P. aeruginosa* in a pipe leading to the faucet in the STC and the RiboPrinter® system revealed that it was the identical strain to the one found in the patients. A simple chlorine rinse of the pipe eradicated the organism and the infections did not return.

Only the RiboPrinter® system's precise, fast, strain-level typing could have enabled hospital staff to pinpoint their cleanup efforts at the source of the nosocomial infection, saving the hospital time and money and minimizing the suffering of patients.

**What can the RiboPrinter® system do for you?**

**Find out. Call 1.800.863.6842.**

**In Europe, call +44 (0) 1926.404008.**

**Qualicon™**  
A DuPont Subsidiary



9 out of 10 mice prefer the Consumer Information Catalog online. Just point and click your way to [www.pueblo.gsa.gov](http://www.pueblo.gsa.gov) and you'll find more than 250 free publications ready to read or download.

U.S. General Services Administration